Exelixis (EXEL) Earnings Beat and FDA Approval Boost Stock Amidst Label Expansion and Valuation Debate.

Exelixis (EXEL) reported earnings that beat expectations, driven by higher Cabometyx sales and FDA approval for zanzalintinib in metastatic colorectal cancer. Despite recent gains, the 30-day share price return declined 6.1% and the year-to-date return declined 5.4%. The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation position Exelixis to invest in next-generation discovery and strategic partnerships, making it an attractive investment opportunity. However, concentration of Cabometyx sales above 90% and rival cancer therapies eroding future pricing power are key risks to consider.